"The results are a worst-case scenario for Novo. Cagrisema is only as good as Zepbound, but more complex to manufacture." "First headline Phase III CagriSema obesity data disappoint with 20.4% ...
Novo reported that, in a late-stage study, a next-generation obesity drug called CagriSema led patients to lose 20% of their weight at 68 weeks when looking at all participants — less than the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback